Although peripheral neuropathy is one of the most common neurologic problems seen in the primary care setting, recognizing and evaluating peripheral neuropathy in a patient can be challenging due to its diverse presentations.
Neuropathic-like knee pain may be driven by central risk factors that include depression, anxiety, and pain catastrophizing.
The treatment is currently being evaluated in a Phase 2 study (ELEVATE) in patients with major depressive disorder who have had an inadequate response to standard antidepressant therapy.
The efficacy of a diagnostic nerve block may be a poor predictor of the success of surgery for focal nerve injury.
A reduction in the functional connectivity between the sensorimotor cortex and the anterior cingulate cortex and dorsolateral prefrontal cortex may be associated with δ-9-tetrahydrocannabinol-associated analgesia in patients with chronic radicular neuropathic pain.
The primary outcome measure was pain rated in a diary completed by telephone each evening; secondary outcomes included measures of overall status, pain-related activity limitation, and sleep.
The non-aqueous adhesive patch requires 36mg per topical system to achieve the same therapeutic dose as Lidoderm (lidocaine 5%) which contains 700mg per patch.
Chart with medications used to treat neuropathic pain, including diabetic peripheral neuropathy, fibromyalgia, and postherpetic neuralgia.
Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
Individuals with knee osteoarthritis who have indicators of high vs low/no levels of neuropathic pain may be at elevated risk for chronic pain after total knee replacement surgery.
Investigators examined whether chronic pain and hypoesthesia are linked in patients with MS.
Neuropathic-like symptoms may affect pain-related quality of life ratings and function in patients with hip and knee osteoarthritis, respectively.
For this review, the authors searched 5 large databases for studies that compared the use of anticonvulsants (i.e., topiramate, gabapentin, pregabalin) in adult patients with LBP, sciatica, or neurogenic claudication with placebo.
Ultrasound-guided pulsed radiofrequency applied to intercostal nerves may be safe and effective for managing thoracic postherpetic neuralgia-associated pain.
A sustained-release formulation of sodium nitrite may not be associated with headaches and dizziness reported by patients treated with the immediate-release formulation of sodium nitrite for diabetic peripheral neuropathy.
Patients with subacute spinal cord injury may present electroencephalographic features that predate the onset of neuropathic pain and may serve both as markers and predictors of neuropathic pain.
Pain in patients with multiple sclerosis may affect their daily functioning regardless of disease severity.
Childhood cancer survivors are at risk for long-term peripheral neuropathy, particularly when treated with cisplatin.
Investigators hypothesize that needle and laser acupuncture may improve clinical and subjective symptoms in patients with diabetic peripheral neuropathy.
A point-of-care conduction device may provide accurate measurements of nerve amplitude potential and conduction velocity for the diagnosis of polyneuropathy in older patients.
The use of a topical capsaicin 8%may be effective in neuropathic pain associated with postherpetic neuralgia or resulting from trauma or surgery.
Specific countries officially recommend some screening questionnaires for the early assessment of neuropathic pain, with France recommending the DN4 and Germany recommending PainDETECT.
A number of factors that include age, the presence of enthesitis, and depressive symptoms may be associated with neuropathic pain in ankylosing spondylitis.
Pain catastrophizing may be associated with reduced psychological — and to a lesser extent physical —function in patients with neuropathic pain and spinal pain.
Percutaneous transluminal angioplasty maybe beneficial for reducing headaches in relapsing remitting and secondary progressive multiple sclerosis.
Patients with V3 trigeminal neuralgia may get greater benefit from bipolar vs unipolar radiofrequency thermocoagulation.
Neuropathic pain is associated with a more severe multiple sclerosis disease phenotype.
Reviewing the Efficacy, Safety, and Tolerability of Cannabis-Based Medicines for Chronic Neuropathic Pain
The effectiveness of cannabis-based products for chronic neuropathic pain is not supported by high-quality evidence.
The type of sciatic nerve lesions observed in patients with diabetic peripheral neuropathy was found to differ in type 1 and type 2 diabetes.
ZTlido is comprised of a non-aqueous adhesive material containing 1.8% lidocaine.
Cotargeting of peripheral μ-opioid and cannabinoid receptors was found to have a synergistic effect in reducing mechanical allodynia in a mouse model of neuropathic pain.
Resilience may mediate the relationships between positive affect and pain interference and depression in patients with multiple sclerosis.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds